U.K. agency suggests restriction on use of drug-eluting stents

09/24/2008 | FDAnews

The use of drug-eluting stents should be limited to coronary-artery disease patients who would likely require future interventions if they received a conventional bare-metal stent instead, according to a final guidance from the U.K.'s National Institute for Health and Clinical Excellence. NICE's final guidance offers data on specific drug-coated stents and their individual prices.

View Full Article in:

FDAnews

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX